Last reviewed 2026-04-23 · How we verify

Optimized drug therapy

Unknown mechanism; insufficient public data available for this investigational therapy.

Unknown mechanism; insufficient public data available for this investigational therapy. Used for Cardiovascular disease prevention (inferred from sponsor focus).

At a glance

Mechanism of action

This appears to be an optimized drug therapy in phase 3 development by an Italian cardiovascular research center, but specific mechanistic details, molecular targets, and pharmacological properties are not publicly disclosed or available in standard pharmaceutical databases.

Approved indications

• Cardiovascular disease prevention (inferred from sponsor focus)

Common side effects

No common side effects on file.

Key clinical trials

• Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (PHASE2)
• HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients (PHASE3)
• Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis (NA)
• Monitoring of the Sympathetic/Vagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV)
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (PHASE2, PHASE3)
• Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial (NA)
• A Study of Soticlestat in Adults and Children With Rare Epilepsies (PHASE2)
• Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.